ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Lowered by Tang Capital Management LLC

Tang Capital Management LLC decreased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 29.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 317,500 shares of the specialty pharmaceutical company's stock after selling 132,500 shares during the period. ANI Pharmaceuticals makes up approximately 1.2% of Tang Capital Management LLC's holdings, making the stock its 22nd largest position. Tang Capital Management LLC owned approximately 1.51% of ANI Pharmaceuticals worth $17,551,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ANIP. US Bancorp DE increased its position in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after purchasing an additional 531 shares during the period. KBC Group NV raised its position in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at $166,000. Rafferty Asset Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth $200,000. Finally, Bridgefront Capital LLC acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter worth $204,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock traded up $0.23 during mid-day trading on Friday, hitting $57.50. 81,166 shares of the company were exchanged, compared to its average volume of 300,705. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $77.00. The company has a market capitalization of $1.25 billion, a P/E ratio of -104.53 and a beta of 0.56. The business's 50 day simple moving average is $66.62 and its two-hundred day simple moving average is $60.80. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $197.12 million during the quarter, compared to analysts' expectations of $179.75 million. During the same quarter last year, the business posted $0.82 EPS. The firm's quarterly revenue was up 43.4% compared to the same quarter last year. Analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective for the company. Guggenheim reaffirmed a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Wall Street Zen cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Truist Financial raised their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Finally, JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $80.13.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the business's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. The trade was a 0.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Christopher Mutz sold 4,000 shares of the stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the sale, the insider now directly owns 107,317 shares of the company's stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,681 shares of company stock valued at $408,498 over the last 90 days. Insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.